Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
KORU Medical Systems, Inc. is a U.S.-based medical technology company focused on the development, manufacture, and commercialization of subcutaneous infusion systems. The company operates within the medical devices and drug delivery industries, with a primary emphasis on chronic disease management. KORU’s core products are designed to deliver life-saving and life-sustaining therapies in home and alternate-site settings, supporting a shift away from hospital-based care.
The company’s principal revenue driver is its proprietary Freedom Infusion Systems, which are used primarily for subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiency and other chronic conditions. KORU serves specialty pharmacies, home infusion providers, hospitals, and biopharmaceutical partners. Its strategic positioning is built on deep specialization in subcutaneous delivery, long-standing clinical adoption, and a large installed base. Founded originally as Repro-Med Systems, the company rebranded to KORU Medical Systems in 2021 to reflect a broader strategic focus on innovation and partnership in drug delivery.
Business Operations
KORU Medical Systems generates revenue through the sale of infusion pumps, tubing sets, consumables, and related accessories, as well as through collaborations with pharmaceutical and biotechnology companies. Its operations are organized around core commercial activities in the U.S. market, international sales primarily through distributors, and emerging partnerships supporting novel drug therapies that require subcutaneous administration.
The company conducts its business primarily through its operating subsidiary Repro-Med Systems, Inc., which manages manufacturing, quality, regulatory compliance, and commercial operations. KORU controls proprietary mechanical infusion technology rather than electronic pump platforms, which differentiates its systems through simplicity, reliability, and suitability for home use. Internationally, the company relies on distribution partners rather than owned manufacturing facilities, allowing capital-efficient global reach.
Strategic Position & Investments
KORU’s strategic direction centers on expanding the use of subcutaneous delivery for both established and emerging therapies, particularly as pharmaceutical developers seek alternatives to intravenous administration. Growth initiatives include increased penetration of international markets, expansion of clinical indications for SCIg therapy, and deeper integration with biopharmaceutical partners during drug development.
The company has invested in supporting novel therapies by adapting its infusion systems for use with new biologics and specialty drugs, positioning itself as a long-term delivery partner rather than a commodity device supplier. KORU has not historically pursued large acquisitions, instead favoring organic growth, targeted product enhancements, and strategic collaborations aligned with its core infusion technology. Data inconclusive based on available public sources regarding material equity investments or large-scale acquisitions.
Geographic Footprint
KORU Medical Systems is headquartered in Mahwah, New Jersey, and its primary commercial market is North America, where the majority of revenue is generated. The company maintains a strong presence in the U.S. home infusion and specialty pharmacy ecosystem, supported by direct sales and clinical education teams.
Internationally, KORU operates across Europe, Asia-Pacific, and parts of Latin America through third-party distributors. These regions represent a growing portion of the company’s strategic focus, particularly in countries with expanding reimbursement for home-based immunoglobulin therapy. While manufacturing and corporate functions remain U.S.-based, the company’s infusion systems are used globally in both developed and emerging healthcare markets.
Leadership & Governance
KORU Medical Systems is led by an executive team with experience in medical devices, specialty pharmaceuticals, and regulated healthcare markets. Leadership emphasizes disciplined growth, clinical collaboration, and long-term partnerships with therapy developers and providers.
Key executives include:
- Allison E. Helt – Chief Executive Officer
- Thomas J. Wisniewski – Chief Financial Officer
The company operates under a public-company governance structure, with oversight from an independent board of directors. Management’s stated strategic vision focuses on enabling patient-centric care, expanding access to subcutaneous therapies, and positioning KORU as a preferred delivery platform for next-generation biologics.